Pomalidomide: all 181 studies that test it

Page 1 of 2. Open to participants first (38), then studies with results posted, then the rest; newest registration first within each.

• Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)Not yet recruitingNCT07831122Phase 1
• Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple MyelomaRecruitingNCT07825064Phase 2
• Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line ResponseNot yet recruitingNCT07760610Phase 4
• Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.Not yet recruitingNCT07757412Phase 2
• Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCLRecruitingNCT07749365Phase 2
• Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.Not yet recruitingNCT07748689Phase 2
• A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple MyelomaNot yet recruitingNCT07728188Phase 3
• Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or LymphomaRecruitingNCT07532525Phase 1
• Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell LymphomaRecruitingNCT07523737Phase 2
• A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT07312188Phase 2
• Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell LymphomaRecruitingNCT07257510Not applicable
• A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07138209Phase 3
• Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple MyelomaRecruitingNCT07096778Phase 2
• The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM PatientsNot yet recruitingNCT07015021Not applicable
• A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsRecruitingNCT06892522Phase 1/2
• A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple MyelomaRecruitingNCT06768489Phase 1
• Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm StudyRecruitingNCT06455748Not applicable
• Daratumumab for Patients With Light Chain AmyloidosisRecruitingNCT06376214Not applicable
• Bortezomib, Pomalidomide, Dexamethasone for Systemic AL AmyloidosisRecruitingNCT06342466Phase 2
• A Pilot Bioequivalence Study of PomalidomideNot yet recruitingNCT06058689Phase 1
• Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple MyelomaRecruitingNCT05922501Phase 2
• Pro-miniCHOP-like Regimen for Treatment-naive Elderly PatientsRecruitingNCT05809180Not applicable
• Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple MyelomaRecruitingNCT05789303Phase 2
• A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple MyelomaRecruitingNCT05651932Phase 1
• A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide RefractoryNot yet recruitingNCT05581875Phase 1/2
• A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)RecruitingNCT05519085Phase 3
• Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSLRecruitingNCT05390749Phase 2
• Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasRecruitingNCT05389423Phase 1
• Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple MyelomaRecruitingNCT05378971Not applicable
• Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell LymphomaRecruitingNCT05348213Phase 2
• A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome InhibitorNot yet recruitingNCT05298683Phase 2
• Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk MyelomaRecruitingNCT05208307Phase 2
• A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Phase 1/2
• Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMMRecruitingNCT04941937Phase 2
• A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT04910568Phase 1
• Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIVRecruitingNCT04902443Phase 1
• A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple MyelomaRecruitingNCT04661137Phase 2
• Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaRecruitingNCT04508790Phase 2
• Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMMActive, not recruitingNCT07150104Phase 1/2Results posted
• Isa-Pom-Dex in Elderly/Frail Subjects With RRMMActive, not recruitingNCT05911321Phase 2Results posted
• Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple MyelomaTerminatedNCT05288062Phase 2Results posted
• Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma PatientsTerminatedNCT04843579Phase 2Results posted
• Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related ChangesActive, not recruitingNCT04802161Phase 2Results posted
• A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple MyelomaTerminatedNCT04700176Phase 2Results posted
• A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to DaratumumabActive, not recruitingNCT04302324Phase 2Results posted
• Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib TripletCompletedNCT04191616Phase 2Results posted
• A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple MyelomaActive, not recruitingNCT04181827Phase 3Results posted
• Pomalidomide for the Treatment of Bleeding in HHTCompletedNCT03910244Phase 2Results posted
• An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma TreatmentsCompletedNCT03828292Phase 1Results posted
• Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple MyelomaCompletedNCT03713294Phase 2Results posted
• Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus InfectionCompletedNCT03601806Phase 2Results posted
• A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple MyelomaTerminatedNCT03567616Phase 2Results posted
• PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple MyelomaCompletedNCT03269136Phase 1Results posted
• A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain TumorsCompletedNCT03257631Phase 2Results posted
• Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple MyelomaCompletedNCT03202628Phase 2Results posted
• Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple MyelomaActive, not recruitingNCT03030261Phase 2Results posted
• Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple MyelomaCompletedNCT02939183Phase 1Results posted
• A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.CompletedNCT02612779Phase 2Results posted
• Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT02547662Phase 2Results posted
• 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple MyelomaTerminatedNCT02289222Phase 1/2Results posted
• Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple MyelomaCompletedNCT02119468Phase 1/2Results posted
• Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT02011113Phase 2Results posted
• A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple MyelomaTerminatedNCT01999335Phase 1Results posted
• Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref MyelomaTerminatedNCT01979276Phase 1/2Results posted
• Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT01946152Phase 1/2Results posted
• Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With LenalidomideCompletedNCT01794039Phase 2Results posted
• Bendamustine + Pomalidomide + Dex in R/R Multiple MyelomaActive, not recruitingNCT01754402Phase 1/2Results posted
• Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT01734928Phase 3Results posted
• Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple MyelomaCompletedNCT01712789Phase 3Results posted
• Pomalidomide for Chronic Graft-versus-Host DiseaseCompletedNCT01688466Phase 2Results posted
• A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL AmyloidosisCompletedNCT01570387Phase 1/2Results posted
• Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung DiseaseTerminatedNCT01559129Phase 2Results posted
• Pomalidomide for Kaposi Sarcoma in People With or Without HIVCompletedNCT01495598Phase 1/2Results posted
• Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple MyelomaCompletedNCT01324947Phase 3Results posted
• Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple MyelomaCompletedNCT01319422Phase 2Results posted
• A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion StudyCompletedNCT01311687Phase 3Results posted
• Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01212952Phase 1/2Results posted
• Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom MacroglobulinemiaTerminatedNCT01198067Phase 1Results posted
• Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-DependenceCompletedNCT01178281Phase 3Results posted
• Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple MyelomaCompletedNCT01177735Phase 2Results posted
• Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory MyelomaCompletedNCT01159574Phase 2Results posted
• Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's MacroglobulinemiaTerminatedNCT01078974Phase 1Results posted
• MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple MyelomaCompletedNCT00833833Phase 1/2Results posted
• CC-4047 (Pomalidomide) for Graft vs. Host DiseaseCompletedNCT00770757Phase 2Results posted
• Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue SarcomaTerminatedNCT00717522Phase 2Results posted
• CC-4047 in Treating Patients With MyelofibrosisCompletedNCT00669578Phase 1/2Results posted
• CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or AmyloidosisCompletedNCT00558896Phase 2Results posted
• CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the PancreasCompletedNCT00540579Phase 1/2Results posted
• A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and EtoposideTerminatedNCT00537511Phase 1/2Results posted
• A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid MetaplasiaCompletedNCT00463385Phase 2Results posted
• Bioequivalence Study Comparing Two Pomalidomide 4 mg Capsule Formulations in Healthy Male SubjectsCompletedNCT07694011Phase 1
• Pomalidomide as an Immune-enhancing Agent for the Control of HIVActive, not recruitingNCT06660498Phase 1/2
• A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Phase 3
• Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Phase 3
• A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Phase 3
• A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After TreatmentActive, not recruitingNCT05556798Phase 1
• Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative StudyCompletedNCT05555329Phase 4
• Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and DexamethasoneStatus unknownNCT05509374Phase 2
• A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentActive, not recruitingNCT05455320Phase 3
• PVd Versus Vd in NDMM Patients With RIStatus unknownNCT05432414Phase 2

← Pomalidomide overview